Rapid Dose Therapeutics Corp (TSE:DOSE) has released an update.
Rapid Dose Therapeutics Corp., a diversified health and wellness company, has reported a significant revenue increase of 42% for the fiscal year 2024, although operating expenses and net comprehensive loss saw slight increases. The company has expanded its product range and developed strategic partnerships, notably entering the pharmaceutical space with an oral anesthesia for dental use and launching erectile dysfunction products.
For further insights into TSE:DOSE stock, check out TipRanks’ Stock Analysis page.
